Business
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 Am
About this update from Beyondspring, Inc.
[{"type":"image","alt":"BeyondSpring, Inc.","displaySize":"","headline":null,"caption":"BeyondSpring, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Bghz8dW7swdFa3BYEYshGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Bghz8dW7swdFa3BYEYshGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89}},"lazy":false},{"type":"text","content":"FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL.","length":609,"tagName":"p"},{"type":"text","content":"Presentation details are as follows:","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: A Phase 2 Study of Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab (Pemb) in Metastatic NSCLC (mNSCLC) After Acquired Resistance (AR) to Anti-PD-1/L1 Alone or in Chemotherapy Combination: Efficacy and Immunophenotyping","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter/Authors: Yan Xu, Minjiang Chen, Xiaoxing Gao, Huiyu Huang, Yue Chang, Xiao-Yian Liu, Wei Zhong, Jing Zhao, RuiLi Pan, Taisheng Li, Mengzhao Wang","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Time: Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: McCormick Place, Chicago, IL","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Lung Cancer – Non-Small Cell Metastatic","length":48,"tagName":"p"}]},{"va...